Start here
Tacrolimus ointment works, and it gets abandoned at the pharmacy counter more than almost anything I prescribe, because of the warning on the box. That warning came from animal studies at doses far above anything skin absorbs, and twenty years of large studies have not found the lymphoma it describes. I use it on the face, the eyelids and skin folds, where months of steroid would thin the skin and this will not. The stinging in the first week is real and it goes away — saying that up front is what keeps people on it.
— Dr. Schwarz, Board Certified Dermatologist
Key Facts
−
| Also called | Protopic |
| Drug class | Topical calcineurin inhibitor — a non-steroid anti-inflammatory |
| Applied as | 0.03% and 0.1% ointment |
| Typical course | Twice daily during flares, then often twice weekly to prevent them |
| Time to work | Itch within days, skin over 1 to 3 weeks |
| Prescription only | Yes |
What It Is
−
Tacrolimus is a prescription ointment approved in 2000 for moderate to severe atopic dermatitis — eczema — when other treatments are unsuitable. The 0.03% strength is licensed from age two, the 0.1% from age sixteen. The same drug is given by mouth, at far larger doses, to stop the body rejecting a transplanted organ. That is where its reputation comes from. On skin, almost none of it reaches the bloodstream. It is not a steroid, so it does not thin skin — which is why it goes on the face, eyelids, neck and skin folds.
How It Works
−
T cells only make inflammatory signals after an internal switch called calcineurin is thrown. Tacrolimus enters the cell, binds a carrier protein, and the pair blocks calcineurin. The T cell then stops producing interleukin-2 and the other messengers that keep an eczema patch inflamed and itchy. It quiets mast cells and the immune cells in the outer layer of skin the same way.
That narrow target explains the rest. Tacrolimus acts on immune cells, not on the fibroblasts that make collagen, so it causes none of the thinning, stretch marks or visible vessels that limit strong steroids on thin skin. The molecule is large and greasy and crosses healthy skin poorly, so blood levels are usually undetectable and fall further as the barrier repairs. First-week burning is a separate effect on nerve endings in inflamed skin, which is why it fades as the rash settles instead of building with use.
Here is where Tacrolimus (Protopic) acts in the skin, and what the others do instead.
About Tacrolimus (Protopic)
Compare
Skin basics
The redness, swelling and itch are the immune system reacting, not the damage itself. Tacrolimus (Protopic) turns that reaction down where it is happening, in the skin, which is why a rash settles within days. Not a steroid: it blocks calcineurin inside the immune cell. It does not thin the skin, so it suits eyelids, face and folds. It stings for the first few days.
Tacrolimus is a large molecule and crosses poorly through healthy skin — more easily through skin that is already inflamed. It gets in where it is needed and much less where it is not.
In a plaque, skin cells travel from the bottom of the epidermis to the surface in four to six days instead of a month, and pile up as scale. This slows them back down, so the plaque thins.
The outer film of dead cells and oil. It holds water in and keeps irritants out, and it is thinner than a sheet of paper. Almost every dry, itchy, stinging skin problem starts here.
The outer layer, and the only one anything in a jar reaches. It renews itself constantly: a cell made at the bottom takes about a month to reach the surface and flake off. Most of what a skincare product does, it does here.
The living layer underneath, holding the blood vessels, the nerves and the collagen. It is where lasting change happens and it is hard to reach: most of what is sold for the skin never gets this far.
What It Treats
−






Not the Best For
−
Forms
−
One form, an ointment, in two strengths.
Greasy, slow to absorb, shiny for a while afterward. That suits dry eczema and irritates people using it on the face in the morning. There is no cream, lotion or scalp version. Pimecrolimus, the milder drug in the same class, comes as a cream — the usual pick for daytime facial use.
Strengths
−
Two strengths, chosen by age and by where the ointment is going, not by escalating until something works.
Basics
−
Sample Routine
−
Here is where Tacrolimus (Protopic) sits in a day, and what goes around it. Pick what you are treating and what your skin is like, and the rest of the routine changes to suit.
What to Expect
−
What to Avoid
−
- Alcohol while using it A flushed, warm face and neck after a drink is recognized and harmless, and it stops when the drug does.
- Strong sun and tanning beds The label advises limiting ultraviolet exposure on treated skin. Sunscreen and a hat on a treated face anyway.
- Sealing the area under a dressing A tight dressing increases absorption and is not how the drug was studied.
- Applying it to infected skin Treat cold sores, impetigo or a spreading warm rash first. Quieting immune activity on top of an infection is the wrong order.
- Open, weeping skin Absorption is greater and stinging is worse. Wait until the surface is intact.
- The eye itself Eyelid skin is a main use. Keep it off the lid margin and out of the eye.
Monitoring
−
No blood tests are needed. Blood levels are usually undetectable with the ointment and fall further as the barrier repairs — the opposite of the oral form used after transplants. Monitoring is a check at two to three weeks on whether the rash responded, then a plan for maintenance.
The boxed warning is the part to understand. It says long-term safety is not established, that rare cases of lymphoma and skin cancer were reported in people who used these drugs, and that continuous long-term use should be avoided. It was added in 2006, based mainly on animal studies using very high doses by mouth or injection, plus scattered case reports.
What has happened since matters. Large cohort studies, and a registry that followed treated children for a decade, have not found the rise in lymphoma the warning describes. Guidelines in the United States and Europe still recommend these drugs, including on the face and eyelids and as twice-weekly maintenance. The concern was theoretical, more than twenty years of use has not borne it out, and how long to continue is still a decision to make with a doctor.
Day-to-day monitoring is simple: keep skin checks routine, use sun protection on treated areas, and pause during a skin infection.
If You Stop
−
No taper, no withdrawal. Stop when the patch clears and restart when it comes back. Eczema tends to return within weeks on the areas that always flare. Twice-weekly maintenance is the licensed answer, and it beats waiting for the next flare and starting over. There is no rebound of the kind that can follow stopping a strong steroid on the face. That is one of the reasons this drug exists.
Cost
−
Both strengths come as generics, which brought the price down a long way, though it still costs more than a generic steroid ointment. Prices vary widely between pharmacies and discount cards sometimes beat insurance, so check more than one. Prior authorization is still common, usually asking that a topical steroid was tried first. Tube size is the practical variable: twice-daily use means a small tube treating a child's face lasts far longer than the same tube on two hands.
Ask Your Doctor
−
How It Compares
−


Myths
+
- "It causes cancer." The boxed warning reports rare cases and says long-term safety is not established. It does not establish that the drug caused them. Studies following large numbers of treated people for years, including a ten-year registry of treated children, have not found the increase.
- "It is a steroid." It is not. It blocks a switch inside T cells and has no effect on collagen, so it does not thin skin.
- "It is the same as the transplant tablets." Same drug, different setting. The tablets give a body-wide dose that needs blood monitoring. With the ointment, blood levels are usually undetectable.
- "You cannot use it near the eyes." Eyelid eczema is one of the main reasons it is prescribed. Keep it off the eye itself.
- "The burning means it is damaging my skin." A nerve effect, not damage. Worst in the first days, typically gone within a week.
Questions Patients Ask
+
Is the cancer warning real?
Yes, and it is printed on the label — long-term safety is not established, and rare cases were reported. Studies following large groups for years have not found the increased risk. A caution, not a demonstrated harm.
Why does it burn?
It acts on nerve endings in inflamed skin as well as on immune cells. Burning is worst in the first few days and gone within a week as the rash heals.
Can I use it on my eyelids?
Yes — eyelid eczema is one of the main reasons it gets prescribed. Keep it off the eye itself and the lid margin.
Why did my face go red after a glass of wine?
Alcohol flushing is a known effect while using it. Harmless, and it stops when the treatment does.
Can I use it indefinitely?
The label asks for the shortest suitable use and for breaks. Twice-weekly maintenance on trouble spots is licensed and widely used. Make that decision with a doctor rather than leaving a prescription running.
Do I need blood tests?
No. Blood levels are usually undetectable with the ointment. The tablets are a different treatment entirely.
References
+
- Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. 2023. — The Journal of allergy and clinical immunology, 2023
- Lax SJ, Van Vogt E, Candy B, et al. Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2024. — Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2024
- Rüegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Annals of the rheumatic diseases. 2025. — Annals of the rheumatic diseases, 2025
- Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical pharmacology and therapeutics. 2015. — Clinical pharmacology and therapeutics, 2015
